Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes

Diabetes Care

Volumn 33, Issue 6, 2010, Pages 1153-1158

  Redmon, J Bruce ^a   Bertoni, Alain G ^b   Connelly, Stephanie ^c   Feeney, Patricia A ^b   Glasser, Stephen P ^d   Glick, Henry ^e   Greenway, Frank ^f   Hesson, Louise A ^e   Lawlor, Michael S ^g   Montez, Maria ^h   Montgomery, Brenda ⁱ  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^g WAKE FOREST UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CALORIC INTAKE; CALORIC RESTRICTION; CARDIOVASCULAR RISK; FEMALE; FITNESS; HEALTH CARE COST; HEALTH EDUCATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNET; LIFESTYLE MODIFICATION; MALE; NATIONAL HEALTH ORGANIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CARE; PHARMACY; PHYSICAL ACTIVITY; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECONOMICS; EXERCISE; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS; WEIGHT LOSS;

EID: 77956071596     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2090     Document Type: Article

References (24)

1. Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med 2009;361:2252-2260
2. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-172 (Pubitemid 46052519)
3. Global Guideline for Type 2 Diabetes [article online], 2005. Available from http://www.idf. org/home/index.cfm?node=1457. Accessed August 2008
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342 (Pubitemid 38101606)
5. American Diabetes Association. Standards of medical care in diabetes, 2008. Diabetes Care 2008;31(Suppl. 1):S12-S54
6. Hood RC: It can be done. Diabetes Care 2003;26:3359-3360
7. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012 (Pubitemid 29254858)
8. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002;324: 1577-1580
9. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-1224
10. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care 2007;30:2478-2483
11. Colllins RW, Anderson JW. Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women. Prev Med 1995;24:369-374
12. Wolf AM, Conaway MR, Crowther JQ, Hazen KY, Nadler JL, Oneida B, Bovbjerg VE. Translating lifestyle intervention to practice in obese patients with type 2 diabetes. Diabetes Care l 2004;27:1570-1576
13. Anderson JW, Conley SB, Nicholas AS. One hundred-pound eeight losses with an intensive behavorial program: changes in risk factors in 118 patients with long-term follow-up. Am J Clin Nutr 2007;86:301-307
14. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374-1383
15. Bray G, Gregg E, Haffner S, Pi-Sunyer XF, WagenKnecht LE, Walkup M, Wing R. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res 2006;3:202-215 (Pubitemid 44902488)
16. Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, Kahn SE, Knowler WC, Yanovski SZ. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-628
17. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the evidence report: National Institutes of Health. Obes Res 1998;6(Suppl. 2):51S-209S
18. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care 2003;26:16-23
19. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007;167:1145-1151
20. Davidson MB. Triple therapy: definitions, application, and treating to target. Diabetes Care 2004;27:1834-1835
21. Hemmelgarn B, Levesque LE, Suissa S. Anti-diabetic drug use and the risk of motor vehicle crash in the elderly. Can J Clin Pharmacol 2006;13:e112-e120 (Pubitemid 46165606)
22. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730 (Pubitemid 350005153)
23. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
24. American Diabetes Associations. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615